Sign in with Google. Opens in new tab
bullish
I-Mab Placement - Heading in the Right Direction
304 Views08 Feb 2021 06:33
A group of shareholders plans to raise around US$200m via selling a 4.6% stake in I-Mab (IMAB US). We have previously covered the IPO as well.
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 4-minute read)
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »- BoE Still Seeking Evidence
- Foshan Haitian Flavouring & Food (3288 HK): Offering Details & Index Inclusion
- [Japan Event] Potentially Interesting Dynamics of Post-Tender NTT Data (9613) Trading. $8bn+ One Way
- Quiddity Leaderboard CSI 300/500 Dec25: US$5bn+ One Way Flows; Emphasis Should Be on NET Flows
- Foshan Haitian Flavouring A/H Trading - Very Strong Demand, Weak Price Momentum
Top Unpaywalled Insights
More »- VEON (VEON US): Launches Third Phase of Share Buyback Program After Share Pullback
- Valuations, Visas & Venture Pullback: An Equity + M&A Overview of the Education Sector in Q1 2025
- Overview #27 – The Big Beautiful Tragi-Comedy Continues
- HK Connect SOUTHBOUND Flows (To 13 June 2025); Volumes Up, TECH Down, HEALTHCARE Bought Big
- [IO Technicals 2025/24] Downward Momentum Lingers
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Changchun High & New Tech (000661.CH) - Insights on Recent Pullback & The Future Business Outlook27 May 2021
- Everest Medicines (1952.HK) - The Commercialization Prospect Has Reshaped24 May 2021
- I-Mab (IMAB US) - Insights On Core Products TJC4, TJ202 and TJ10129 Mar 2021
- I-Mab (天境生物) Lock-Up Expiry: A Differentiated Immunotherapy Player Worth Reverse Inquiry08 Jul 2020
- I-Mab (天境生物) IPO Trading: Tiny Float and Undemanding Valuation17 Jan 2020
- I-Mab (天境生物) IPO: Everest Deal a Valuation Booster06 Jan 2020
x